Hoping to ease shortage, FDA fast-tracks generic form of cancer drug

Hoping to ease shortage, FDA fast-tracks generic form of cancer drug
Agency says new availability of doxorubicin will help people battling malignancy.

(HealthDay)—Seeking to ease potentially dangerous shortages of a key cancer drug, the U.S. Food and Drug Administration on Monday announced it had fast-tracked the approval of the first generic form of one such medication, Doxil (doxorubicin).

"The agency is committed to doing everything we can to address so that patients can get the medicines they need when they need them," Capt. Valerie Jensen, director of the Drug Shortage Staff at the FDA's Center for and Research, said in an agency news release. "For the past year, the FDA has been working to ensure that supplies of [] were not interrupted."

The new is made by Sun Pharma Global and will be available in 20 milligram and 50 milligram vials. Like brand-name Doxil, the injected drug is administered intravenously by a health care professional.

approved by the FDA have the same quality and strength as brand name drugs, and the generic manufacturing and packaging sites must pass the same quality standards as those of brand name drugs, the agency noted.

In response to the Doxil shortage, the FDA announced in February 2012 that it would allow temporary controlled importation of Lipodox, an alternative to Doxil that is produced by Sun Pharma Global but not approved in the United States.

The FDA also decided to allow the release of one lot of Janssen's Doxil made under an unapproved manufacturing process.

For the time being, the FDA said it will continue to allow the controlled importation of Lipodox. Once there is enough of Sun's generic version to meet projected demand, the FDA will halt imports of any unapproved doxorubicin product.

Shortages of potentially life-saving cancer medications have plagued the U.S. for the past two years.

Speaking at the annual meeting of the American Society for Clinical Oncology last June, Dr. Richard Schilsky, chair of ASCO's government relations committee, told reporters that some shortages had eased, "but there is still an unpredictable availability of many drugs and we are never sure exactly when a generic drug is suddenly going to go out of supply."

According to Schilsky, "that creates a tremendous amount of uncertainty—anxiety for our patients and great difficulty in planning if you're a physician."

In October of 2011, President Barack Obama signed a special Executive Order demanding action on the issue, which is often caused by interruptions in manufacturing as companies address safety issues.

Besides Doxil, other drugs that have seen interruptions in supply include nitrogen mustard (used to fight blood cancers), paclitaxel (important for breast cancer and other tumors), 5-FU (used in a variety of cancers), and methotrexate (important to treat certain lymphomas).

More information: The U.S. Food and Drug Administration has more about drug shortages.

add to favorites email to friend print save as pdf

Related Stories

FDA: New suppliers to ease 2 cancer drug shortages

Feb 21, 2012

Federal regulators said Tuesday that they've approved new suppliers for two crucial cancer drugs, easing critical shortages - at least for the time being - that have patients worried about missing life-saving treatments.

US House sends drug bill to Senate for final vote

Jun 20, 2012

(AP) — The House on Wednesday passed a major bill affecting the Food and Drug Administration that will increase inspections of drug manufacturing facilities overseas, while also funding review of new drugs at home.

First generic lexapro approved

Mar 14, 2012

(HealthDay) -- The Israeli drug maker Teva Pharmaceuticals has gained the first U.S. approval to market generic Lexapro (escitalopram) to treat depression and general anxiety disorder, the U.S. Food and Drug Administration ...

Recommended for you

Study recalculates costs of combination vaccines

Apr 17, 2014

One of the most popular vaccine brands for children may not be the most cost-effective choice. And doctors may be overlooking some cost factors when choosing vaccines, driving the market toward what is actually a more expensive ...

Drug watchdog urges vigilance in cancer drug theft

Apr 17, 2014

Europe's medicine watchdog urged doctors Thursday to be vigilant in administering the cancer drug Herceptin, vials of which had been stolen in Italy and tampered with before being sold back into the supply chain.

User comments